{"id":"W2912998652","doi":"10.1038/s41586-019-0974-0","title":"Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers","year":2019,"lang":"en","type":"erratum","venue":"Nature","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Loxo Oncology; Genentech; EMD Serono; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Eli Lilly and Company; Chinese University of Hong Kong; Juno Therapeutics; Eisai; Daiichi-Sankyo; Puma Biotechnology; Aminex Therapeutics; Symphogen; Pfizer; Incyte; Ipsen; Five Prime Therapeutics; Les Laboratories Pierre Fabre; BioMarin Pharmaceutical; Sanofi; Sierra Oncology; Genomic Health; Clovis Oncology; Varian Medical Systems; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Spectrum Pharmaceuticals; Jounce Therapeutics; Celgene; Servier; Foghorn Therapeutics; AstraZeneca; Bristol-Myers Squibb","keywords":"Mutant; Cancer research; Kinase; Internal medicine; Biology; Oncology; Medicine; Genetics; Gene","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003090318,0.001679607,0.001747957,0.002575541,0.002024997,0.002710593,0.002587257,0.007600832,0.02008617],"category_scores_gemma":[0.03913844,0.0008451652,0.001688582,0.001238403,0.00149544,0.001249934,0.001027204,0.01226149,0.01141495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003480821,"about_ca_system_score_gemma":0.004058129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01243176,"about_ca_topic_score_gemma":0.01759548,"domain_scores_codex":[0.9970696,0.0005201779,0.0005069764,0.0004177324,0.001184109,0.0003014819],"domain_scores_gemma":[0.9832134,0.005578204,0.0009215498,0.0008044587,0.008347109,0.001135174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002611443,0.000004180697,0.00005773255,0.00005455671,0.00001102021,0.0004744202,0.000008721458,0.00002641957,0.00002244525,0.0002383428,0.9961451,0.002930969],"study_design_scores_gemma":[0.0001173258,0.00003718115,0.0008923299,0.0003749758,0.0001083445,0.00259694,0.00006057031,0.000319775,0.0004375301,0.001135553,0.9938758,0.00004355864],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0001172877,0.0009941614,0.0002534059,0.07264526,0.9240198,0.00001012628,0.0004319326,0.00009862796,0.001429463],"genre_scores_gemma":[0.01589636,0.01024211,0.003374839,0.1888921,0.6296365,0.0001515939,0.001435055,0.0008662393,0.1495052],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.02008617,"threshold_uncertainty_score":0.06719494,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0103670938512117,"score_gpt":0.3107062440311836,"score_spread":0.3003391501799719,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}